<DOC>
	<DOCNO>NCT02070991</DOCNO>
	<brief_summary>Study evaluate macitentan safe tolerable enough used treatment subject combine pre- post-capillary pulmonary hypertension ( CpcPH ) due leave ventricular dysfunction .</brief_summary>
	<brief_title>Clinical Study Evaluate Safety Tolerability Macitentan Subjects With Combined Pre- Post-capillary Pulmonary Hypertension ( CpcPH ) Due Left Ventricular Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1 . Males Females &gt; =18 year age 2 . Subjects combine preand postcapillary Pulmonary Hypertension ( CpcPH ) due leave ventricular dysfunction ( subset WHO group 2.1 2.2 ) 3 . Optimized diuretic therapy 1 . Types Pulmonary Hypertension WHO group 2.1 2.2 ( Nice classification ) 2 . Administration PAHspecific therapy ( i.e. , Endothelin receptor antagonist ( ERAs ) , Prostanoids , Phosphodiesterase 5 ( PDE5 ) inhibitor , guanylate cyclase stimulators )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pre- post-capillary pulmonary hypertension</keyword>
	<keyword>CpcPH</keyword>
</DOC>